Amylyx to present Phase 3 LUCIDITY results for avexitide at ObesityWeek on Nov 15, NDA planned by year end

Amylyx Pharmaceuticals will present Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia as a late-breaking oral at ObesityWeek on November 15, with an NDA submission planned by year end.

Detected & updated continuously · Source: Nebula